S17 Ep41: Dissecting INDEPENDENCE Data and the Role of Luspatercept in Myelofibrosis-Associated Anemia: With Claire Harrison, MD

In today’s episode, we welcomed Claire Harrison, MD, a professor of myeloproliferative neoplasms and clinical director at Guy's and St Thomas' NHS Foundation Trust in London, United Kingdom.In the exclusive interview, Dr Harrison discussed management strategies for anemia in patients with myelofibrosis and the implications of the phase 3 INDEPENDENCE trial (NCT04717414) presented at the 2026 EHA Congress. Dr Harrison detailed the prevalence and current challenges in managing myelofibrosis-associated anemia. She also detailed key efficacy outcomes reported for luspatercept-aamt (Reblozyl) in the INDEPENCENCE study, along with outlining some of the factors that contributed to the study narrowly missing statistical significance for its primary end point of red blood cell transfusion independence for at least 12 consecutive weeks during the first 24 weeks of treatment.